VEGFB and neoplasm: In addition, further investigation is needed to comprehensively characterize the mechanisms by which Pja2 and VEGF-B inhibit the conformational activation of β1 integrin in the vascular endothelium both in culture and in vivo models of, e.g., tumor angiogenesis.